NA Proactive news snapshot: Cloud DX, New Oroperu Resources, Todos Medical, Kainantu Resources, CleanSpark UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Cloud DX Inc (CVE:CDX) said Brad Miller, a director of the company (formerly Roosevelt Capital Group), as a result of the previously announced qualifying transaction and related transactions, had acquired beneficial ownership and control over 7,307,337 shares and 100,000 share purchase warrants issued to B and M Miller Equity Holdings Inc - an entity controlled by Mr Miller. The shares and warrants were issued in exchange for the securities of Cloud Canada held by B&M prior to completion of the qualifying transaction. As a result of the qualifying transaction, B&M has ownership and control over 10.13% of the shares on a non-diluted basis and around 10.28% of the shares on a partially diluted basis assuming t
NA Proactive news snapshot: The Good Shroom Co, Golden Minerals, Codebase Ventures, Vicinity Motor …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
The Good Shroom Co Inc. (CVE:MUSH), previously Cluny Capital Corp, (CVE:CLN.H), a Toronto Venture Exchange (TSX) capital pool company, has announced the completion of its qualifying transaction, which involved the amalgamation of Teonan Biomedical Inc. with the company s wholly-owned subsidiary, as part of a three-cornered amalgamation between the parties. Immediately prior to the transaction, the company was continued under the Canada Business Corporations Act, its outstanding common shares were consolidated on a 3 for 1 basis and, the company changed its name to The Good Shroom Co Inc. (Les Bons Champignons Inc.).
NA Proactive news snapshot: Todos Medical, Kainantu Resources, CleanSpark, Arcadia Biosciences UPDATE …
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Todos Medical Ltd (OTCQB:TOMDF) has announced the initiation of a randomized, double-blind, placebo-controlled Phase 2 clinical trial of antiviral Tollovir for the treatment of hospitalized coronavirus (COVID-19) patients. The trial is being conducted at Shaare Zedek Medical Center in Jerusalem, Israel, and will evaluate the safety and efficacy of Tollovir, the company said. Tollovir is a patent-pending therapeutic agent being developed through a joint venture between Todos and NLC Pharma. It is among 3CL protease inhibitors that are targeted as desirable candidates for the development of antiviral therapies against SARS-CoV-2, the virus that causes the COVID-19 disease.
Real Luck Group Adds VALORANT Game Betting to Luckbox Platform investingnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from investingnews.com Daily Mail and Mail on Sunday newspapers.